Relative risk (RR) of PTLDs by method of T-cell depletion of the bone marrow, ATG therapy, HLA and GVHD status, second transplantation, and age at transplantation
| Variable . | Patients . | PTLDs . | RR (95% CI) . |
|---|---|---|---|
| Part I: Main model* | |||
| T-cell depletion methods | |||
| Broad lymphocyte depletion (see Part II) | 1196 | 6 | 3.1 (1.2-6.7) |
| Selective T-cell depletion (see Part II) | 2350 | 68 | 9.4 (6.0-14.7) |
| ATG use (preventive or acute GVHD treatment†) | 2269 | 39 | 3.8 (2.5-5.8) |
| 2+ HLA antigen–mismatched related or unrelated donor, no ATG, no selective T-cell depletion | 2699 | 4 | 0.9 (0.3-2.2) |
| 2+ HLA antigen–mismatched related or unrelated donor, ATG and/or selective T-cell depletion | 1375 | 55 | 3.8 (2.4-6.1) |
| Acute GVHD grade II-IV† | 10 575 | 62 | 1.7 (1.2-2.5) |
| Chronic GVHD moderate/severe or clinical extensive† | 4771 | 22 | 2.0 (1.1-3.2) |
| Second transplantation† | 1471 | 11 | 3.5 (1.7-6.3) |
| Age 50 y or older at transplantation | 945 | 14 | 5.1 (2.8-8.7) |
| Part II: T-cell depletion methods‡ | |||
| No T-cell depletion | 23 355 | 53 | 1.0 |
| Broad lymphocyte depletion | |||
| Alemtuzumab (CAMPATH) MoAb | 684 | 3 | 3.1 (0.7-8.4) |
| Elutriation/density gradient centrifugation | 512 | 3 | 3.2 (0.8-8.8) |
| Selective T-cell depletion | |||
| Anti-T or anti-T+NK MoAb | 1784 | 49 | 8.4 (5.1-13) |
| SRBC rosetting | 225 | 7 | 14.6 (5.9-31) |
| Lectins with/without SRBC or anti-T MoAb§ | 223 | 10 | 15.8 (7.2-32) |
| Unclassified/unknown method | 118 | 2 | 6.0 (0.96-20) |
| Variable . | Patients . | PTLDs . | RR (95% CI) . |
|---|---|---|---|
| Part I: Main model* | |||
| T-cell depletion methods | |||
| Broad lymphocyte depletion (see Part II) | 1196 | 6 | 3.1 (1.2-6.7) |
| Selective T-cell depletion (see Part II) | 2350 | 68 | 9.4 (6.0-14.7) |
| ATG use (preventive or acute GVHD treatment†) | 2269 | 39 | 3.8 (2.5-5.8) |
| 2+ HLA antigen–mismatched related or unrelated donor, no ATG, no selective T-cell depletion | 2699 | 4 | 0.9 (0.3-2.2) |
| 2+ HLA antigen–mismatched related or unrelated donor, ATG and/or selective T-cell depletion | 1375 | 55 | 3.8 (2.4-6.1) |
| Acute GVHD grade II-IV† | 10 575 | 62 | 1.7 (1.2-2.5) |
| Chronic GVHD moderate/severe or clinical extensive† | 4771 | 22 | 2.0 (1.1-3.2) |
| Second transplantation† | 1471 | 11 | 3.5 (1.7-6.3) |
| Age 50 y or older at transplantation | 945 | 14 | 5.1 (2.8-8.7) |
| Part II: T-cell depletion methods‡ | |||
| No T-cell depletion | 23 355 | 53 | 1.0 |
| Broad lymphocyte depletion | |||
| Alemtuzumab (CAMPATH) MoAb | 684 | 3 | 3.1 (0.7-8.4) |
| Elutriation/density gradient centrifugation | 512 | 3 | 3.2 (0.8-8.8) |
| Selective T-cell depletion | |||
| Anti-T or anti-T+NK MoAb | 1784 | 49 | 8.4 (5.1-13) |
| SRBC rosetting | 225 | 7 | 14.6 (5.9-31) |
| Lectins with/without SRBC or anti-T MoAb§ | 223 | 10 | 15.8 (7.2-32) |
| Unclassified/unknown method | 118 | 2 | 6.0 (0.96-20) |
RR indicates relative risk; PTLD, posttransplantation lymphoproliferative disorder; CI, confidence interval; chronic GVHD, mild or moderate graft-versus-host disease for CIBMTR or clinical extensive FHCRC; NK, natural killer; MoAb, monoclonal antibodies; ATG, antithymocyte globulin; and SRBC, sheep red blood cell rosetting methods including SRBC plus density gradient centrifugation.
Part I: Poisson regression analysis stratified by time since transplantation in 13 categories (Table 2).
The following variables are time dependent: ATG, acute GVHD, chronic GVHD, and second transplantation. Second allogeneic transplantation among patients with a first allogeneic transplantation.
Part II model includes all variables in part I model with additional variables for T-cell depletion methods.
Group includes methods that remove both B and T cells (lectin agglutinations) and methods that selectively target T cells.